Medicamen Biotech cash flow

Latest FY26

Cash from operations: −₹33.2cr−₹7.2 cr in FY25
Capital spending: ₹4.8cr+130.4% on FY25
Free cash flow: −₹38.0cr−₹9.3 cr in FY25
Cash from financing: ₹63.7cr−₹1.9 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	7.2	7.1	7.1	6.4
	—	0.0	0.0	0.0	−0.0
	—	3.5	3.2	4.4	0.0
	—	0.0	0.0	0.0	0.0
	—	−7.9	−2.8	−14.3	−18.0
	—	−12.9	−13.7	10.0	−2.0
	—	1.0	0.0	0.0	0.0
	—	−3.7	0.0	0.0	0.0
	—	−9.8	1.8	5.2	−0.2
	—	−14.0	−2.1	−20.0	−10.9
	—	−2.6	3.8	−2.2	4.3
	—	1.0	−9.1	0.2	−2.1
	—	0.0	0.0	0.0	0.2
	—	−3.1	−4.1	0.0	0.0
Cash from operating activities
	12.4	12.0	9.9	13.1	17.0
	—	−41.4	−15.8	−9.7	−22.4
	—	−29.4	−6.0	3.4	−5.4
	—	−1.7	0.5	−0.7	−0.7
	—	0.0	−0.4	0.0	2.9
	—	2.0	1.4	3.1	3.1
	—	−33.2	−7.2	−0.4	−6.3
Cash from investing activities
	—	4.8	2.1	0.0	6.6
	—	0.0	0.0	6.3	0.0
	—	0.0	0.3	0.0	0.0
	—	1.7	0.5	0.7	0.7
	—	−3.0	−1.9	−5.6	−5.9
Cash from financing activities
	—	0.8	0.9	0.1	33.4
	—	52.7	0.0	1.8	0.0
	—	0.0	0.0	2.9	0.0
	—	14.5	1.6	6.2	−0.2
	—	0.0	0.0	−0.4	0.0
	—	3.5	3.2	4.4	2.9
	—	1.4	1.3	1.3	1.3
	—	0.5	0.0	0.0	0.1
	—	63.7	−1.9	−0.1	29.1
	—	27.5	−11.0	−6.0	17.0
	—	27.5	−11.0	−6.0	17.0
	—	—	—	14.8	20.8
Reference items
	19.3	19.6	13.9	22.2	23.9
	9.5%	9.9%	8.5%	12.4%	17.0%
	−38.0	−38.0	−9.3	−6.7	−12.9
	—	−26.9	−10.0	−4.4	—
	−₹27.98	−₹27.98	−₹6.83	−₹4.91	−₹9.51
	—	−3.39×	−1.10×	−0.04×	−0.43×
	—	2.0	1.4	3.1	3.1
	—	3.5	3.2	4.4	2.9

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

MEDICAMEQ₹254.25

Medicamen Biotech Limited

· Pharma & Health

₹ CrorePeersMEDICO AAREYDRUGS NECLIFE HALEOSLABS ALBERTDAVD NATCAPSUQ VALIANTLAB BALPHARMAMcap ₹345 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	6.4	7.1	7.1	7.2	—
+ Impairment Loss / (Reversal)	-0.0	0.0	0.0	0.0	—
+ Finance Costs	0.0	4.4	3.2	3.5	—
+ Other Non-cash Items	0.0	0.0	0.0	0.0	—
Changes in Working Capital
+ Inventories	-18.0	-14.3	-2.8	-7.9	—
+ Trade Receivables — Current	-2.0	10.0	-13.7	-12.9	—
+ Other Financial Assets — Current	0.0	0.0	0.0	1.0	—
+ Other Financial Assets — Non-current	0.0	0.0	0.0	-3.7	—
+ Other Current Assets	-0.2	5.2	1.8	-9.8	—
+ Other Non-current Assets	-10.9	-20.0	-2.1	-14.0	—
+ Trade Payables — Current	4.3	-2.2	3.8	-2.6	—
+ Other Current Liabilities	-2.1	0.2	-9.1	1.0	—
+ Other Non-current Liabilities	0.2	0.0	0.0	0.0	—
+ Provisions — Current	0.0	0.0	-4.1	-3.1	—
Cash from Operating Activities
Profit Before Tax (per I/S)	17.0	13.1	9.9	12.0	12.4
+ Total Adjustments (incl. Working Capital)	-22.4	-9.7	-15.8	-41.4	—
Cash from Operations (pre-tax)	-5.4	3.4	-6.0	-29.4	—
+ Interest Received — Operating	-0.7	-0.7	0.5	-1.7	—
+ Other Inflows / (Outflows) — Operating	2.9	0.0	-0.4	0.0	—
+ Income Taxes Paid	3.1	3.1	1.4	2.0	—
Cash from Operating Activities	-6.3	-0.4	-7.2	-33.2	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	6.6	0.0	2.1	4.8	—
+ Acq of Intangible Assets	0.0	6.3	0.0	0.0	—
+ Acq of Other Long-term Assets	0.0	0.0	0.3	0.0	—
+ Interest Received — Investing	0.7	0.7	0.5	1.7	—
Cash from Investing Activities	-5.9	-5.6	-1.9	-3.0	—
Cash from Financing Activities
+ Proceeds from Issue of Shares	33.4	0.1	0.9	0.8	—
+ Proceeds from Other Equity Instruments	0.0	1.8	0.0	52.7	—
+ Payments for Other Equity Instruments	0.0	2.9	0.0	0.0	—
+ Proceeds from Borrowings	-0.2	6.2	1.6	14.5	—
+ Repayment of Borrowings	0.0	-0.4	0.0	0.0	—
+ Interest Paid	2.9	4.4	3.2	3.5	—
+ Dividends Paid	1.3	1.3	1.3	1.4	—
+ Other Inflows / (Outflows) — Financing	0.1	0.0	0.0	0.5	—
Cash from Financing Activities	29.1	-0.1	-1.9	63.7	—
Net Changes in Cash (pre-FX)	17.0	-6.0	-11.0	27.5	—
Net Changes in Cash	17.0	-6.0	-11.0	27.5	—
Closing Cash	20.8	14.8	—	—	—
Reference Items
EBITDA	23.9	22.2	13.9	19.6	19.3
EBITDA Margin %	16.95	12.40	8.53	9.90	9.52
Free Cash Flow (CFO − Capex)	-12.9	-6.7	-9.3	-38.0	-38.0
Free Cash Flow to Equity	—	-4.4	-10.0	-26.9	—
Free Cash Flow per Basic Share	-9.51	-4.91	-6.83	-27.98	-27.98
Cash Flow to Net Income	-0.43	-0.04	-1.10	-3.39	—
Cash Paid for Taxes	3.1	3.1	1.4	2.0	—
Cash Paid for Interest	2.9	4.4	3.2	3.5	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.